Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics is reshaping its legal leadership, appointing Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026, while Lori J. Braender steps down from those executive roles and continues as Corporate Secretary.
Braender will provide transition services and receive her current base salary through May 7, 2026, plus a pro rata 2026 bonus, 12 months of severance-style monthly payments equal to 1/12 of her prior base salary and target bonus, and 12 months of continued health and life insurance coverage. All of her unvested equity awards will fully vest on May 7, 2026, and options and similar awards will remain exercisable for at least five years or until their scheduled expirations.
For her ongoing non-executive role, Braender will earn a base salary of $15,000 per month and remain eligible for senior executive benefit plans. To induce Zalewski to join, the company will grant 100,000 Restricted Stock Units and 75,000 stock options under its 2022 Equity Inducement Plan, vesting over three years, with the options carrying a ten-year term and an exercise price set at the closing price on May 8, 2026.
Aquestive Therapeutics Chief People Officer Peter E. Boyd reported equity awards and a mandated tax-related share sale. On March 9, he received 80,000 shares of restricted Common Stock that vest over three annual installments (25%, 25%, 50%), and a non-qualified stock option for 42,500 shares of Common Stock at $4.29 per share, expiring on March 9, 2036, with the same vesting pattern.
On March 10, 29,814 shares of Common Stock were sold at a weighted average price of $4.173 per share solely to cover tax withholding obligations tied to restricted stock unit vesting, as required by the company’s equity plans and not as discretionary trading. After these transactions, Boyd directly holds 338,509 shares of Common Stock plus the newly granted option for 42,500 shares.
Aquestive Therapeutics President and CEO Daniel Barber reported compensation-related equity activity and a mandated tax sale. On March 9, 2026, he received 262,000 shares of restricted Common Stock at no cost and 523,000 non-qualified stock options with a $4.29 exercise price, each vesting 25%, 25%, then 50% over three annual installments. On March 10, 2026, he sold 180,677 Common shares at a weighted average price of $4.173 in trades between $4.17 and $4.33 to cover tax withholding obligations from restricted stock unit vesting, as required by the company’s equity plan, rather than as discretionary trading. After the sale, he directly owned 1,004,753 Common shares and held the newly granted options for 523,000 underlying shares.
Aquestive Therapeutics Chief Legal Officer Lori J. Braender received new equity awards and executed a tax-related share sale. She was granted 80,000 shares of restricted stock, which will vest in three annual installments of 25%, 25%, and 50%. She also received 50,000 non-qualified stock options to buy common stock at $4.29 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. On March 10, 2026, she sold 40,102 shares of common stock at a weighted average price of $4.173 per share to cover tax withholding obligations from restricted stock unit vesting, a mandated “sell to cover” transaction rather than a discretionary trade. After these transactions, she directly holds 442,879 shares of common stock.
Aquestive Therapeutics SVP Melina Cioffi reported a mix of stock grants and tax-related sales. She received 100,000 shares of restricted common stock at no cost and a grant of options for 75,000 shares at a $4.29 exercise price, both vesting over three annual installments of 25%, 25%, and 50%.
On a separate date, she sold 25,311 common shares at a weighted average price of $4.173 per share to cover tax withholding tied to restricted stock unit vesting, a transaction mandated by the company’s equity plans rather than a discretionary trade. After these transactions, she directly holds 274,867 common shares.
Aquestive Therapeutics Chief Financial Officer Ernest A. Toth Jr. reported a mix of equity compensation awards and a related share sale. He received 95,000 shares of common stock as a grant and a non-qualified stock option for 70,000 shares of common stock with a $4.29 exercise price, expiring on March 9, 2036. Both the restricted stock and options vest over three annual installments of 25%, 25%, and 50%. On March 10, 2026, he sold 58,254 shares of common stock at a weighted average price of $4.173 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from the vesting of restricted stock units and were mandated under the company’s equity incentive plan, rather than being discretionary trades. After the sale, he directly held 376,112 shares of common stock and the newly granted option for 70,000 shares.
Aquestive Therapeutics Chief Commercial Officer Sherry Korczynski reported a mix of equity awards and related share sales. She received 75,000 shares of restricted common stock and a non-qualified stock option for 42,500 shares at $4.29 per share, vesting in three annual installments of 25%, 25% and 50%. In connection with the vesting of restricted stock units, she sold 15,741 common shares at a weighted average price of $4.173 per share to cover tax withholding obligations under the company’s equity plan, which the footnotes state were mandated “sell to cover” transactions rather than discretionary trades. After these transactions, she directly holds 241,117 common shares and the newly granted option expiring in 2036.
Aquestive Therapeutics, Inc. Chief Operating Officer Cassie Jung reported a combination of equity grants and a mandated share sale. She received 80,000 shares of restricted common stock and a non-qualified stock option for 42,500 shares at an exercise price of $4.29 per share, vesting over three annual installments. To cover tax withholding from restricted stock unit vesting, she sold 45,791 shares of common stock at a weighted average price of $4.173 per share in transactions described as required "sell to cover" trades rather than discretionary sales. After these moves, she directly holds 274,980 common shares and indirectly holds 2,000 shares through her spouse, along with the newly granted option expiring on March 9, 2036.
Aquestive Therapeutics, Inc. reported that its Chief Development Officer, Matthew W. Davis, received new equity compensation. On March 9, 2026, he was granted a non-qualified stock option for 50,000 shares of common stock at an exercise price of $4.29 per share, expiring on March 9, 2036. He was also granted 50,000 shares of restricted common stock at no cash cost. The restricted stock will vest in three annual installments with 25% on the first installment, 25% on the second, and 50% on the third, and the option will vest on the same schedule. Following these grants, his direct common stock holdings reported in this filing total 100,000 shares.
Greenhawt Matthew J. reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics Chief Medical Officer Matthew J. Greenhawt received new equity awards. He was granted a non-qualified stock option for 50,000 shares of Common Stock at $4.29 per share, expiring on March 9, 2036. The option vests in three annual installments of 25%, 25%, and 50%.
He also received 75,000 shares of restricted Common Stock at no cost, vesting on the same 25%, 25%, and 50% schedule. Following these grants, he holds 75,000 shares of Common Stock directly, 50,000 option shares directly, and 2,000 shares indirectly through his spouse.